- Home
- DNTH vs TXO Comparison
DNTH vs TXO Comparison
Compare DNTH & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- TXO
- Stock Information
- Founded
- DNTH 2015
- TXO 2012
- Country
- DNTH United States
- TXO United States
- Employees
- DNTH N/A
- TXO N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- DNTH Health Care
- TXO Energy
- Exchange
- DNTH Nasdaq
- TXO Nasdaq
- Market Cap
- DNTH 568.6M
- TXO 788.6M
- IPO Year
- DNTH N/A
- TXO 2023
- Fundamental
- Price
- DNTH $18.85
- TXO $15.27
- Analyst Decision
- DNTH Strong Buy
- TXO
- Analyst Count
- DNTH 8
- TXO 0
- Target Price
- DNTH $53.00
- TXO N/A
- AVG Volume (30 Days)
- DNTH 315.6K
- TXO 312.6K
- Earning Date
- DNTH 08-07-2025
- TXO 08-05-2025
- Dividend Yield
- DNTH N/A
- TXO 15.78%
- EPS Growth
- DNTH N/A
- TXO N/A
- EPS
- DNTH N/A
- TXO 0.40
- Revenue
- DNTH $6,524,000.00
- TXO $299,696,000.00
- Revenue This Year
- DNTH N/A
- TXO $33.41
- Revenue Next Year
- DNTH N/A
- TXO $9.20
- P/E Ratio
- DNTH N/A
- TXO $37.85
- Revenue Growth
- DNTH 102.36
- TXO 3.43
- 52 Week Low
- DNTH $13.37
- TXO $14.78
- 52 Week High
- DNTH $32.27
- TXO $21.72
- Technical
- Relative Strength Index (RSI)
- DNTH 54.07
- TXO 45.71
- Support Level
- DNTH $17.27
- TXO $15.01
- Resistance Level
- DNTH $19.46
- TXO $15.39
- Average True Range (ATR)
- DNTH 1.07
- TXO 0.40
- MACD
- DNTH 0.15
- TXO 0.02
- Stochastic Oscillator
- DNTH 76.74
- TXO 26.67
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.